White matter lesions disrupt cholinergic pathways important for cognition in Parkinson’s disease
Clicks: 1
ID: 313830
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #344 of 375 articles by views in Brain research
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 375 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
White matter lesions are associated with cognitive impairment in Parkinson's disease, but the underlying neurobiological mechanisms remain unclear. One hypothesis is that strategically located white matter lesions disrupt long-range white-matter pathways crucial for cognitive functioning, particularly cholinergic projections from the basal forebrain, contributing to cognitive decline. Using volumetric measures of basal forebrain nuclei (T1 MRI proxy for brain cholinergic projection nuclei), quantitative white matter lesions assessments (fluid-attenuated inversion recovery MRI), and a presynaptic cholinergic marker ([18F]-FEOBV PET), we tested a mechanistic model of white matter lesions effects on basal forebrain cholinergic projections and nuclei, and how these disruptions relate to cognition. We analysed data from 127 mid to advanced-stage patients with Parkinson's disease without dementia. Periventricular and deep white matter lesion burdens were quantified with the UBO Detector pipeline. Cognitive function was assessed across five domains using z-scores from a control group matched for age and education. Voxel-wise analyses examined associations between white matter lesion burden and cholinergic synaptic density, followed by mediation analyses testing whether cholinergic alterations mediated the relationship between white matter lesions and cognition, while correcting for sex, levodopa equivalent dose, and disease duration. Voxel-wise analyses revealed that higher periventricular lesions burden was associated with reduced [18F]-FEOBV uptake in an insular-limbic-frontal-cingulum cluster, while deep lesions showed more topographically limited associations that disappeared after adjusting for periventricular burden. Periventricular lesions affected lateral and external Ch4 cholinergic projection pathways (81%-88% of patients), more frequently than deep white matter lesions (25%-47% of patients), except for the external capsule, which was equally affected by both. Cognitive performance (global cognition, memory, executive function, and attention) was associated with both periventricular lesion burden and [18F]-FEOBV uptake within the insular-limbic-frontal-cingulum cluster, as well as with basal forebrain volume. Mediation analyses indicated that periventricular lesions had a direct effect on cortical terminal integrity ([18F]-FEOBV) and an indirect, presumably retrograde degeneration effect via basal forebrain atrophy. The effect of periventricular lesions on insular-limbic-frontal-cingulum cholinergic terminal density was a strong mediator of the association between lesion burden and cognitive performance. A weaker mediation effect via the basal forebrain emerged for global cognition, whereas mediation was more robust for memory and executive functioning. Our findings indicate that periventricular white matter lesions contribute to cognitive vulnerability in Parkinson's disease without dementia through impacts on basal forebrain cholinergic projections. White matter lesion burden may represent a mechanistically meaningful biomarker for predicting cognitive trajectories and informing targeted interventions in Parkinson's disease.
| Reference Key |
openalex_W7160909523
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Giulia Carli, Taylor Brown, Fotini Michalakis, Abigail Biddix, Stiven Roytman, Robert Vangel, August Van Hout, Prabesh Kanel, Peter Scott, R Albin, Nicolaas I Bohnen |
| Journal | Brain research |
| Year | 2026 |
| DOI |
10.1093/brain/awag172
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.